Low-dose amikacin with appropriate dose adjustment based on adequate monitoring demonstrated limited toxicity with positive outcomes as a treatment option for multidrug-resistant tuberculosis (MDR-TB), according to the findings of a retrospective cohort study published in BMC Infectious Diseases. Read here
The Stop TB Partnership today is releasing the campaign toolkit for this year’s World TB Day, 24 March 2023 Yes! We Can End TB. The theme brings attention toTB and our collective power to end TB by 20
Adding the oxazolidinone antibiotic sutezolid to a three-drug combination appeared to be safe and effective for people with multidrug-resistant tuberculosis (TB), according to a dose-finding phase II
TAG has released its Pipeline Report regarding TB Treatment updates and results from trials completed in 2022 written by Lindsay McKenna. Read the report here!